相关实验视频
Updated: Aug 28, 2026

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse
Published on: September 12, 2018
关于尼普利辛 (NEP) 抑制剂的全面审查:设计,结构-活性关系和临床应用
Xinyue Zhang1, Chun Hu2, Erkang Tian2
1Department of Stomatology, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Chengdu University of TCM, Chengdu, Sichuan, China.
尼普利辛 (NEP) 抑制剂通过调节生物活性来为心血管疾病和阿尔茨海默氏症提供治疗潜力. 本综述详细介绍了单和双NEP抑制剂,重点关注设计,安全性和临床结果.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 尼普里林素 (NEP) 是一种关键的酶,调节,血管和大脑中的生物活性.
- 由于NEP在代谢天然尿素和脑中的作用,使其成为心血管和神经系统疾病的治疗点.
- 目前的NEP抑制剂,如sacubitril显示临床效用,但有相关的不良影响.
研究的目的:
- 审查单标和双标尼普利辛抑制剂的进展.
- 分析NEP抑制剂的设计策略,结构-活性关系 (SAR) 和临床性能.
- 讨论双抑制剂在提高疗效和减轻副作用方面的潜力.
主要方法:
- 对NEP抑制剂的综合文献综述.
- 对NEP抑制的结构-活性关系 (SAR) 的分析.
- 评估已批准和正在研究的NEP抑制剂的临床数据和安全性概况.
主要成果:
- NEP 抑制剂调节有益水平,提供治疗效益.
- 双标NEP抑制剂,通常与其他标 (如血管激素受体) 相结合,有望提高疗效和安全性.
- NEP 抑制剂的副作用包括低血压和功能障碍.
结论:
- NEP 抑制剂代表了心血管和阿尔茨海默氏症疾病的重要治疗策略.
- 双目标抑制策略对于优化治疗结果和管理副作用至关重要.
- 对NEP抑制剂设计和临床应用的进一步研究是有必要的.
更多相关视频
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
14:34A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Tubular Secretion
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions